home / stock / crxtw / crxtw news

CRXTW News and Press, Clarus Therapeutics Holdings Inc. Warrant 9/9/2026 From 05/09/22

Stock Information
Company Name: Clarus Therapeutics Holdings Inc. Warrant 9/9/2026
Stock Symbol: CRXTW
Market: NASDAQ
Website: clarustherapeutics.com
Menu
CRXTW CRXTW Quote CRXTW Short CRXTW News CRXTW Articles CRXTW Message Board
Get CRXTW Alerts

News, Short Squeeze, Breakout and More Instantly...
CRXTW - Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., May 09, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasd...
CRXTW - Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Upon issuance, this patent will be listed in FDA’s Orange Book, bringing the total number of Orange Boo...

CRXTW - Clarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public Offering

NORTHBROOK, Ill., April 27, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the closing of it...

CRXTW - Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering

NORTHBROOK, Ill., April 25, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the pricing of it...
CRXTW - Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the Androgen Society 4th Annual Meeting

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., April 19, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasd...

CRXTW - Clarus Therapeutics Holdings' (CRXT) CEO Bob Dudley on Q4 2021 Results - Earnings Call Transcript

Clarus Therapeutics Holdings, Inc. (CRXT) Q4 2021 Earnings Conference Call March 30, 2022 5:15 PM ET Company Participants Bob Dudley – President and Chief Executive Officer Ric Peterson – Chief Financial Officer Frank Jaeger – Chief Commercial Officer Conference Call Part...

CRXTW - Clarus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

2021 net revenue increased 119% year-over-year to $14.0 million Fourth quarter 2021 net revenue increased 88% year-over-year to $4.6 million Fourth quarter 2021 total prescription growth for JATENZO ® increased 11% sequentially and increased 81% year-over-year ...
CRXTW - Clarus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial and Operating Results

NORTHBROOK, Ill., March 29, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced i...

CRXTW - Clarus Announces Initiation of Phase 4 Clinical Trial of JATENZO® (testosterone undecanoate) for the Treatment of Hypogonadal Men with Chronic Kidney Disease

JATENZO is the first and only FDA-approved oral softgel for testosterone (T) replacement therapy in adult males who have deficient T due to certain medical conditions Clarus expects to announce results from the trial in the first half of 2023 NORTHBROOK, Ill., March 16, 2022...

CRXTW - Clarus Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference

NORTHBROOK, Ill., March 10, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it will pres...
Previous 10 Next 10